Insulet Co. (NASDAQ:PODD) Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC decreased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 1.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 37,594 shares of the medical instruments supplier’s stock after selling 641 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Insulet were worth $8,750,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. QRG Capital Management Inc. purchased a new stake in shares of Insulet in the third quarter worth about $297,000. Diversified Trust Co boosted its holdings in Insulet by 90.9% in the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock worth $1,842,000 after acquiring an additional 4,348 shares during the period. Assenagon Asset Management S.A. grew its position in Insulet by 38.8% in the second quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier’s stock valued at $36,202,000 after acquiring an additional 50,101 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Insulet by 0.9% during the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after purchasing an additional 3,113 shares during the period. Finally, Point72 DIFC Ltd acquired a new position in shares of Insulet during the second quarter worth $554,000.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PODD. Citigroup lifted their price target on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. UBS Group boosted their price target on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Morgan Stanley raised their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Raymond James upped their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Finally, Barclays raised their price target on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $267.58 on Friday. The company has a market cap of $18.77 billion, a PE ratio of 45.82, a P/E/G ratio of 4.12 and a beta of 1.21. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40. The firm has a 50-day simple moving average of $246.17 and a 200 day simple moving average of $215.90. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.